2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1014

Improvement in Mentoring Associated with Implementation of an Inter-Institutional Mentoring Program within Pediatric Rheumatology
Abstract Number: 1015

Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice
Abstract Number: 1016

Collagen Antibodies Induce Pain-like Behavior in Mice Independent of Inflammation and Complement Activation but Requires FcÎ³rs
Abstract Number: 1017

A Novel Mechanism of Arthritis-Induced Pain: Activation of Sensory Neurons By Autoantibodies
Abstract Number: 1018

A 32-Mer Aggrecan Fragment Generated through Adamts-4/5 and MMP-Mediated Cleavage Can Directly Excite Nociceptive Neurons
Abstract Number: 1019

Brain Functional Connectivity Differentially Predicts Response to Two Centrally Acting Analgesics in Fibromyalgia
Abstract Number: 1020

Abnormal Resting State Functional Connectivity in Chronic Fatigue Syndrome Patients: An Arterial Spin-Labeling fMRI Study
Abstract Number: 1021

Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 1022

Identification of Shared Genomic Regions in Distantly Related Pairs of Cases with Juvenile Idiopathic Arthritis
Abstract Number: 1023

Tumor Necrosis Factor-a (TNF-a) and Interferon Gamma Inducible Protein-10 (IP-10) As Predictors of Active Disease Status in Localized Scleroderma
Abstract Number: 1024

Disruptions in Folate Homeostasis May Lead to Increased Risk for Methotrexate Intolerance in Juvenile Idiopathic Arthritis
Abstract Number: 1025

Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI): Genotype-Phenotype Correlation
Abstract Number: 1026

Microrna-125a-5p Has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and Is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro
Abstract Number: 1027

Rheumatoid Arthritis Disease Activity Assessment Frequencies in Clinical Practices Do Not Support Treat-to-Target Care
Abstract Number: 1028

Improving Pneumococcal Immunization Rates Among Immunocompromised Adolescent Patients at a Tertiary Care Children’s Hospital

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].